

PRESS RELEASE  
November 24, 2011

### **Myocardial infarction: one step further in patient care**

*The Cardiovascular Research Center of the "Centre de Recherche Public de la Santé" (CRP Santé) and Firalis SAS, a leading company in biomarker development, have signed a collaboration agreement for the development of an in vitro diagnostic device intended to improve the care of patients who experienced an acute myocardial infarction.*

### **A kit for a better prediction of clinical outcomes after myocardial infarction**

Half of myocardial infarction patients experience mid- to long-term complications. By leveraging new opportunities provided by innovative biomarkers, the collaboration between CRP santé and Firalis therefore aims at developing a biomarker based device to predict complications occurring after heart attacks. This will be enabled thanks to discoveries by Dr. Daniel Wagner, cardiologist at the Luxembourg Hospital and at the National Institute of Cardiac Surgery and Interventional Cardiology, to Dr. Yvan Devaux, co-lead of cardiovascular research at CRP-santé, and to Huningue (France) based Firalis, having a broad experience in the discovery and qualification of biomarkers and in the development of respective diagnostic kits.

The two entities signed a collaborative research agreement associated with an exclusive license option for Firalis. Under the terms of this agreement, Firalis is to develop and commercialize a diagnostic kit based on a combination of biomarkers patented by CRP-Santé. This combination of biomarkers will allow the application of a predictive model, helping doctors to evaluate risks of cardiovascular complications and to choose for the best prevention strategy.

### **An example of public-private partnership**

The Cardiovascular Research Center has started to work on improving therapeutic care of myocardial infarction patients in 2003. Ever since, Dr. Wagner and his team have conducted several projects in this domain. Through the collaboration with Firalis, the Luxembourgish group is intending to extend its commitment toward patient care, and to accelerate the development of new tools for doctors and patients. *"The development of such devices will greatly benefit from the clinical network across Europe that Firalis has been building during the past few years"*, said Dr. Hüseyin Firat, CEO of Firalis. For Firalis, it is an opportunity to capitalize on discoveries made by public research and to apply its development expertise to bring innovative products to the market. The collaboration is also reflecting the effort of Luxembourg to participate in the development of innovative approaches in medicine in order to address most urgent patient needs.

### **About Firalis**

Firalis is a privately owned life sciences company, creating value by discovering novel biomarkers, by their development and regulatory qualification. The company is establishing an internal portfolio of biomarker-based diagnostic methods and provides customer-tailored biomarker solutions. Firalis is active in the field of drug safety, cardiovascular-, inflammatory-, and autoimmune diseases. For its innovative approach, the company has been awarded several national and international prizes. Firalis plays a central role in several industry-wide collaborative projects, such as the SAFE-T consortium. For more information please visit [www.firalis.com](http://www.firalis.com).

### **About CRP-Santé**

The center for public research for health, CRP-Santé, is the main research institution in Luxembourg. CRP-Santé's mission is to build scientific and economic added value in Luxembourg through research and in the field of life science and biomedical research.

CRP santé is organized in 5 main departments: cardiovascular diseases, immunology, oncology, public health, virology/allergy and immunity. These groups are supported by 3 platforms: the Luxembourg biomedical research resources (LBR2), the center for methodology and statistics (CCMS), the center of epidemiology and clinical investigation (CIEC).

The organization employs more than 200 scientists plus 50 administrative agents to advance the 200 on-going research projects. CRP-Santé actively collaborate with other organization in Luxembourg including hospitals, the Luxembourg Center for Systems Biomedicine (LCSB), the Integrated Biobank of Luxembourg (IBBL) and others research organizations. Among its international collaborators, CRP-Santé counts the TGen foundation (Phoenix, Arizona), the Fred Hutchinson Cancer Research Center (Seattle, Washington) and the Institute for System Biology (Seattle, Washington).

---

### **Contact:**

FIRALIS SAS  
35 Rue du Fort, F-68330 Huningue  
[contact@firalis.com](mailto:contact@firalis.com)  
[www.firalis.com](http://www.firalis.com)